Madrigal Pharmaceuticals ... (MDGL)
Madrigal Pharmaceuticals Inc. (MDGL) Stock Price, Analysis & Data
No hay datos disponibles
| Precio de compra | 511.93 |
| Capitalización de mercado | 12.33B |
| Ingresos (TTM) | 1.28B |
| Beneficio neto (TTM) | -325.1M |
| Beta | -1.00 |
| EPS (TTM) | -14 |
| Ratio PER (TTM) | n/a |
| Adelante PE | 55.43 |
| P/B (TTM) | 23.53 |
| P/S (TTM) | 9.60 |
| Earnings Date | Nov 4, 2026 |
| Precio de venta | 512.55 |
| Volumen | 287,368 |
| Volumen medio (20D) | 364,191 |
| Abierto | 524.50 |
| Anterior Cerrar | 524.87 |
| Rango del día | 514.57 - 533.68 |
| Rango de 52 semanas | 374.50 - 615.00 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de MDGL
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania....
Desempeño financiero
En 2025, los ingresos de Madrigal Pharmaceuticals fueron 958.4M, un aumento de 432.05% en comparación con 180.13M del año anterior. Las ganancias fueron -288.28M, una disminución de -38.12%.
Estados financierosSorpresa de resultados
Los analistas proyectan ingresos de ... Actualizar
2 semanas hace · Simply Wall St.
Madrigal Pharmaceuticals (MDGL) Beat Earnings Estimates, Is It Still Below Fair Value?Madrigal Pharmaceuticals (MDGL) drew attention after its second quarter 2026 earnings release, which highlighted Rezdiffra sales growth, stronger patient uptake, a smaller than expected quarterly loss...
